Pcn188 - Assessing the Robustness of a Cost-Effectiveness Analysis of Lenvatinib Versus Sorafenib in Unresectable Hepatocellular Carcinoma in Japan
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.270
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV